ClinicalTrials.gg
TerminatedNCT03442556Updated Aug 26, 2026Results posted

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

A Phase 2 interventional study of Carboplatin and Docetaxel in ATM Gene Mutation, BRCA1 Gene Mutation and BRCA2 Gene Mutation, sponsored by University of Washington. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated due to insufficient funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.

Read the detailed description

OUTLINE:

INDUCTION: Patients receive docetaxel intravenously (IV) and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive rucaparib camsylate orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

02

Conditions studied

  • ATM Gene Mutation
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Castration Levels of Testosterone
  • Castration-Resistant Prostate Carcinoma
  • Homologous Recombination Deficiency
  • Prostate Carcinoma Metastatic in the Bone
  • PSA Level Greater Than or Equal to Two
  • PSA Progression
  • Stage IV Prostate Adenocarcinoma AJCC v7
03

In context

Lead sponsor

University of Washington is the lead sponsor of 1,434 studies on the registry; 225 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information
  • or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
  • Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy; patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy
  • Castration resistant prostate cancer as defined by serum testosterone \< 50 ng/ml and PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart
  • Presence of disease on bone or computed tomography (CT) scan

    • Evaluable disease progression by modified 1.1 (Response Evaluation Criteria in Solid Tumors)
    • Bone disease on bone scan
  • Prior therapy with sipuleucel-T, abiraterone, enzalutamide, docetaxel, and/or cabazitaxel; there is no limit to the number of prior treatment regimens in the castration resistant setting, so long as prior therapy does not include platinum chemotherapy or a PARP inhibitor; prior platinum chemotherapy in the hormone sensitive setting is permitted, so long as it has been at least 6 months since last dose
  • (ECOG) performance status of =\< 1
  • >= 12 weeks
  • No prior is allowed except:

    • Adequately treated basal cell or squamous cell skin cancer or
    • In situ carcinoma of any site or
    • Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)
  • Documented evidence of at least ONE or MORE of the following:

    * Pathogenic mutation or inactivating alteration of a gene involved in homologous recombination repair in the tumor

    • Note, that if this alteration is identified in a circulating tumor deoxyribonucleic acid (ctDNA) assay, the variant-allele fraction must be > 20% to indicate relevance to predominant tumor clone

      • Mutation in one or more other genes involved in homologous DNA recombination repair in the tumor may be included at investigator's discretion
      • Homologous recombination repair deficiency by genomic signature in the tumor by BROCA-HR, Foundation One or equivalent assay
      • Presence of pathogenic or likely pathogenic germline mutation/variant in BRCA2, BRCA1, ATM or PALB2
    • Note: Germline mutations in other HR genes will be considered at investigator's discretion)
  • (ANC) >= 1.5 x 10\^9/L (within 14 days of first dose of study drug)
  • > 100 x 10\^9/L (within 14 days of first dose of study drug)
  • >= 9 g/dL (within 14 days of first dose of study drug)
  • (AST) and alanine aminotransferase (ALT) =\< 3 x ; if liver metastases, then =\< 5 x ULN (within 14 days of first dose of study drug)
  • =\< 1.5 x ULN (\< 2 x ULN if hyperbilirubinemia is due to Gilbert's syndrome) (within 14 days of first dose of study drug)
  • Serum creatinine =\< 1.5 x ULN or estimated (GFR) >= 45 mL/min using the formula (within 14 days of first dose of study drug)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving active therapy for other neoplastic disorders
  • Symptomatic and/or untreated central nervous system (CNS) ; patients with asymptomatic previously treated are eligible provided they have been clinically stable for at least 4 weeks
  • Known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease
  • heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or (NYHA) class II-IV heart disease or cardiac measurement of \< 35 % at baseline
  • Treatment with an therapeutic drug within 30 days of cycle 1
  • Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)
  • Prior therapy with a platinum chemotherapy (e.g. cisplatin, carboplatin, oxaliplatin) in the castration resistant setting; (prior platinum chemotherapy in the hormone sensitive setting is permitted, so long as time since last dose is 6 months or greater)
  • Active, ongoing toxicity ( [CTCAE] grade 2 or higher) from prior therapy
  • Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding and/or giving of
  • Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
  • Any condition(s), medical or otherwise, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment (docetaxel, carboplatin, rucaparib camsylate)

    INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Carboplatin · Drug: Docetaxel · Other: Laboratory Biomarker Analysis · Drug: Rucaparib Camsylate · Drug: Rucaparib

Interventions

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • Given IV

    Also known as: Docecad, RP56976, Taxotere, Taxotere Injection Concentrate

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given PO

    Also known as: 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate

  • Given PO

    Also known as: 283173-50-2, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria

    Radiologic progression free survival (rPFS) is defined as the time from first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by investigator assessment using the RECIST 1.1/PCWG3 criteria.

    Time frame: From first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, assessed up to 3.75 years.

Secondary outcomes

  1. Overall Response Rate (ORR) of Measurable Disease (PCWG3) (Complete Response or Partial Response) Assessed by Modified RECIST Version 1.1 Criteria

    Overall response rate of measurable disease (PCWG3): radiologic ORR (CR or PR per modified RECIST Version 1.1 criteria and no bone progression per PCWG3 prior to a CR or PR) by investigator assessment in patients with measurable visceral and/or nodal disease at baseline per IRR (Cohort A). An analysis of radiologic ORR by the investigator will also be conducted as supportive to the primary endpoint.

    Time frame: Up to 3.75 years

  2. Prostate-specific Antigen (PSA) Nadir After Induction

    Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90). Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90). The change in PSA was calculated relative to the PSA level at the start of cycle 1.

    Time frame: Up to 13 weeks

  3. PSA Nadir After Maintenance

    Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90) using postchemotherapy PSA as the baseline. The most recent PSA level before PARPi initiation was used as the baseline PSA. Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90).

    Time frame: Up to 3.5 years

  4. PSA Response Duration

    PSA-response duration: duration of confirmed response is defined as the time from the date that a response (PSA decrease ≥ 50%) is first reported to the time that PSA progression is first documented.

    Time frame: From the date that a response (PSA decrease >= 50%) is first reported to the time that PSA progression is first documented, assessed up to 3.75 years

  5. Time to PSA Progression (PCWG3)

    Time to PSA progression is defined as the time from first dose of docetaxel/carboplatin to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later.

    Time frame: From first dose of docetaxel/carboplatin to the date that a >= 25% increase and absolute increase of >= 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured, assessed up to 3.75 years.

07

Results

Posted Aug 26, 2026

Participant flow

Induction (docetaxel and carboplatin)
Participant flow — Induction (docetaxel and carboplatin)
MilestoneTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Started18
Completed16
Not completed2
Withdrew: Adverse event1
Withdrew: Death1
Maintenance (rucaparib)
Participant flow — Maintenance (rucaparib)
MilestoneTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Started16
Completed0
Not completed16
Withdrew: Adverse event2
Withdrew: Death1
Withdrew: Disease progression12
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryRadiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria

Radiologic progression free survival (rPFS) is defined as the time from first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by investigator assessment using the RECIST 1.1/PCWG3 criteria.

Time frame:
From first dose of docetaxel/carboplatin to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, assessed up to 3.75 years.
Reported as:
Median · Months
Radiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria
MonthsTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Radiographic Progression Free Survival Assessed by Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1/Prostate Cancer Working Group 3 (PCWG3) Criteria8.1 (6.5 to 31.2)
SecondaryOverall Response Rate (ORR) of Measurable Disease (PCWG3) (Complete Response or Partial Response) Assessed by Modified RECIST Version 1.1 Criteria

Overall response rate of measurable disease (PCWG3): radiologic ORR (CR or PR per modified RECIST Version 1.1 criteria and no bone progression per PCWG3 prior to a CR or PR) by investigator assessment in patients with measurable visceral and/or nodal disease at baseline per IRR (Cohort A). An analysis of radiologic ORR by the investigator will also be conducted as supportive to the primary endpoint.

Time frame:
Up to 3.75 years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) of Measurable Disease (PCWG3) (Complete Response or Partial Response) Assessed by Modified RECIST Version 1.1 Criteria
ParticipantsTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Partial Response3
Stable Disease9
Progressive Disease2
SecondaryProstate-specific Antigen (PSA) Nadir After Induction

Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90). Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90). The change in PSA was calculated relative to the PSA level at the start of cycle 1.

Time frame:
Up to 13 weeks
Reported as:
Count of participants · Participants
Prostate-specific Antigen (PSA) Nadir After Induction
ParticipantsInduction (Docetaxel and Carboplatin)
PSA decline from baseline of ≥50%7
PSA decline from baseline of ≥90%1
PSA decline from baseline of <50%4
PSA Increase6
SecondaryPSA Nadir After Maintenance

Rate of confirmed PSA decrease from baseline, assessed by a local laboratory (PSA50 and PSA90) using postchemotherapy PSA as the baseline. The most recent PSA level before PARPi initiation was used as the baseline PSA. Number of patients achieving a PSA decline from baseline of ≥50% (PSA50) or ≥90% (PSA90).

Time frame:
Up to 3.5 years
Reported as:
Count of participants · Participants
PSA Nadir After Maintenance
ParticipantsMaintenance (Rucaparib Camsylate)
PSA decline from postchemotherapy of ≥50%4
PSA decline from postchemotherapy of ≥90%4
PSA decline from postchemotherapy of <50%1
PSA Increase7
SecondaryPSA Response Duration

PSA-response duration: duration of confirmed response is defined as the time from the date that a response (PSA decrease ≥ 50%) is first reported to the time that PSA progression is first documented.

Time frame:
From the date that a response (PSA decrease >= 50%) is first reported to the time that PSA progression is first documented, assessed up to 3.75 years
Reported as:
Number · Months
PSA Response Duration
MonthsTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Subject 112.43
Subject 20.67
Subject 336.86
Subject 424.03
Subject 512
Subject 64.86
Subject 74.6
Subject 819.86
Subject 94.56
Subject 108.23
SecondaryTime to PSA Progression (PCWG3)

Time to PSA progression is defined as the time from first dose of docetaxel/carboplatin to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later.

Time frame:
From first dose of docetaxel/carboplatin to the date that a >= 25% increase and absolute increase of >= 2 ng/mL above the nadir (or baseline value for patients who did not have a decline in PSA) in PSA was measured, assessed up to 3.75 years.
Reported as:
Median · Months
Time to PSA Progression (PCWG3)
MonthsTreatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Time to PSA Progression (PCWG3)5.2 (3.2 to 20.9)

Adverse events

Collected over Only treatment-emergent adverse events (TEAEs) were collected: TEAEs are defined as AEs with onset date on or after the date of first dose of study drug until the date of the last study drug dose plus 28 days (up to 3.75 years total).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Phase (Docetaxel and Carboplatin)1/18 (5.6%)2/18 (11.1%)18/18 (100%)
Maintenance Phase (Rucaparib Camsylate)1/16 (6.3%)1/16 (6.3%)16/16 (100%)
Most frequent serious events
Most frequent serious events
EventInduction Phase (Docetaxel and Carboplatin)Maintenance Phase (Rucaparib Camsylate)
Intractable VomitingGastrointestinal disorders0/181/16
Cerebral Venous Sinus ThrombosisNervous system disorders0/181/16
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/181/16
Skin ulceration, right footSkin and subcutaneous tissue disorders0/181/16
Starvation KetoacidosisMetabolism and nutrition disorders1/180/16
Acute KetoacidosisMetabolism and nutrition disorders1/180/16
Most frequent other events
Showing 10 of 127
Most frequent other events
EventInduction Phase (Docetaxel and Carboplatin)Maintenance Phase (Rucaparib Camsylate)
FatigueGeneral disorders15/1812/16
AnemiaBlood and lymphatic system disorders11/186/16
NauseaGastrointestinal disorders9/186/16
ConstipationGastrointestinal disorders8/186/16
DiarrheaGastrointestinal disorders8/183/16
AnorexiaMetabolism and nutrition disorders7/185/16
Weight lossInvestigations2/185/16
Elevated creatinineInvestigations1/185/16
HypomagnesemiaMetabolism and nutrition disorders5/183/16
ThrombocytopeniaInvestigations5/184/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
<=18 years0
Between 18 and 65 years6
>=65 years12
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Female0
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported1
PSA at Diagnosis
PSA at Diagnosis(ng/mL)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Participant 116
Participant 25
Participant 342
Participant 4129
Participant 5156
Participant 6540
Participant 76
Participant 8588
Participant 9132
Participant 107
Participant 1125
Participant 1236
Participant 1317
Participant 1413
Participant 152040
Participant 1635
Participant 174374
Participant 181101
Primary treatment (radical prostatectomy or radiation)
Primary treatment (radical prostatectomy or radiation)(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
Prostatectomy5
Radiation1
Neither12
Prior therapies for castration resistant prostate cancer
Prior therapies for castration resistant prostate cancer(Participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
1 Therapy4
2 Therapies8
3 or more Therapies6
BRCA/ATM/other HR gene mutation status
BRCA/ATM/other HR gene mutation status(participants)Treatment (Docetaxel, Carboplatin, Rucaparib Camsylate)
ATM7
BRCA13
BRCA28
PALB21
FANCA1
CHD1 + SPOP1

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jun 2025, 81 months.

Results were first posted in Aug 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 22, 2018
StartActual
Aug 24, 2018
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 4, 2025
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03442556
Responsible party
Heather Cheng (Professor, University of Washington) — Principal investigator
First posted
Feb 22, 2018
Start date
Aug 24, 2018
Primary completion
Jun 4, 2025
Completion
Jun 4, 2025
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Study contacts

Heather H. Cheng
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Docetaxel · Rucaparib

Start the discussion